NEW YORK, Aug. 30 – Galapagos Genomics and the Flanders Interuniversity Institute for Biotechnology have entered a collaboration to identify and validate Alzheimer-related gene targets, the companies announced Thursday.

Under the terms of the collaboration, Galapagos, a privately held company based in Belgium, integrate its PhenoSelect gene function discovery platform with the Flanders Interuniversity Institute for Biotechnology’s (VIB) cell-based presesilin-gamma-secretase assays to screen its human gene library for genes involved in Alzheimer’s Disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.